This study is NOT currently recruiting participants.
Number
03-DK-0257
Sponsoring Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruitment Detail
Type: No longer recruiting/follow-up only Gender: Male & Female Min Age: 5 Years Max Age: 80 Years
Referral Letter Required
Yes
Population Exclusion(s)
None
Keywords
Rabson Mendenhall; Type B Insulin Resistance; Type A Insulin Resistance
Recruitment Keyword(s)
Condition(s)
Severe Insulin Resistance
Investigational Drug(s)
Metreleptin
Investigational Device(s)
Intervention(s)
Drug: Metreleptin
Supporting Site
National Institute of Diabetes and Digestive and Kidney Diseases
Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality. We hypothesize that recombinant leptin (metreleptin) in these patients will improve glycemia control.
Objectives:
Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in patients with genetic defects of the insulin receptor. Secondary Objectives: To determine mechanisms by which metreleptin improves glycemia.
Endpoints:
Primary Endpoint: Hemoglobin A1c.
Secondary Endpoints: fasting plasma glucose, fasting insulin/C-peptide, glucose/insulin/C-peptide area under the curve during oral glucose tolerance test.
Study Population:
20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at the NIH Clinical Center.
Description of Sites/Facilities Enrolling Participants: Description of Study Intervention:
NIH Clinical Center
Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).
--Back to Top--
INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: -Provision of signed and dated informed consent form -Male or female, aged >= 5 years. -Clinically significant, severe insulin resistance caused by a known or suspected defect in the insulin receptor -Presence of at least one of the following metabolic abnormalities: --Fasting insulin >30 micro U/ml, or --Presence of diabetes as defined by the 2006 American Diabetes Association (ADA) criteria: ---Fasting plasma glucose >= 126 mg/dL ---2 hour plasma glucose >= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load, or ---Diabetic symptoms with a random plasma glucose >= 200 mg/dL -Ability of subject Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: -Pregnant at time of enrollment, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing. -Known infectious liver disease -Known HIV infection -Current alcohol or substance abuse -Active tuberculosis -Use of anorexiogenic drugs -Other conditions which in the opinion of the clinical investigators would impede completion of the study. -Subjects who have a known hypersensitivity to E. Coli derived proteins.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-Provision of signed and dated informed consent form
-Male or female, aged >= 5 years.
-Clinically significant, severe insulin resistance caused by a known or suspected defect in the insulin receptor
-Presence of at least one of the following metabolic abnormalities:
--Fasting insulin >30 micro U/ml, or
--Presence of diabetes as defined by the 2006 American Diabetes Association (ADA) criteria:
---Fasting plasma glucose >= 126 mg/dL
---2 hour plasma glucose >= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load, or
---Diabetic symptoms with a random plasma glucose >= 200 mg/dL
-Ability of subject Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
-Pregnant at time of enrollment, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.
-Known infectious liver disease
-Known HIV infection
-Current alcohol or substance abuse
-Active tuberculosis
-Use of anorexiogenic drugs
-Other conditions which in the opinion of the clinical investigators would impede completion of the study.
-Subjects who have a known hypersensitivity to E. Coli derived proteins.
Principal Investigator
Referral Contact
For more information: